Evofem Biosciences, Inc. (EVFM)
Oxford Ledge is still expanding full research coverage of EVFM. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Evofem commercializes PHEXX and SOLOSEC, FDA-approved products for women's sexual and reproductive health in the U.S. and internationally.
SEC filings
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-04-30
- 8-K Entry into material agreement; Financial statements and exhibits 2026-04-16
- 8-K Termination of material agreement; Financial statements and exhibits 2026-03-19
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for EVFM. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open EVFM in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.